KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent…

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 3 news outlets

twitter: 2 X users

Readers on

mendeley: 12 Mendeley

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 5,789 followers.

RT @drteplinsky: @SoMeCME KEYNOTE-826 Outcomes KEYNOTE-826 final OS analysis consistent w/ earlier results & provides further support for p…

@SoMeCME KEYNOTE-826 Outcomes KEYNOTE-826 final OS analysis consistent w/ earlier results & provides further support for pembro + chemo ± BEV as 1L SOC for recurrent or metastatic CC Pembro + chemo outcomes: ↑ Survival ↑ Response ≅ PFS & OS ± BE…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.